NCT03648346View on ClinicalTrials.gov

A Dose-escalation Clinical Trial After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

July 25, 2018

Study Completion Date

January 25, 2019

Conditions
Healthy Subjects
Interventions
DRUG

Cohort 1: HL217 Ophathalmic Solution BID

Two drops of 3 mg/mL of the treatment in one eye twice a day

DRUG

Cohort 2: HL217 Ophathalmic Solution QID

Two drops of 3 mg/mL of the treatment in one eye 4 times a day

DRUG

Placebo

Placebo eye drops

Trial Locations (1)

Unknown

Eurofins OPTIMED, Gières

All Listed Sponsors
lead

Hanlim Pharm. Co., Ltd.

INDUSTRY

NCT03648346 - A Dose-escalation Clinical Trial After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects | Biotech Hunter | Biotech Hunter